AC Immune Statistics
Total Valuation
AC Immune has a market cap or net worth of $164.25 million. The enterprise value is -$12.39 million.
Important Dates
The next estimated earnings date is Monday, May 12, 2025, before market open.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
AC Immune has 98.94 million shares outstanding. The number of shares has increased by 17.71% in one year.
| Current Share Class | 98.94M |
| Shares Outstanding | 98.94M |
| Shares Change (YoY) | +17.71% |
| Shares Change (QoQ) | -0.86% |
| Owned by Insiders (%) | 3.60% |
| Owned by Institutions (%) | 8.23% |
| Float | 39.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.49 |
| Forward PS | n/a |
| PB Ratio | 1.35 |
| P/TBV Ratio | 2.41 |
| P/FCF Ratio | 2.09 |
| P/OCF Ratio | 2.26 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.71, with a Debt / Equity ratio of 0.05.
| Current Ratio | 1.71 |
| Quick Ratio | 1.66 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.08 |
| Interest Coverage | -393.82 |
Financial Efficiency
Return on equity (ROE) is -37.31% and return on invested capital (ROIC) is -23.23%.
| Return on Equity (ROE) | -37.31% |
| Return on Assets (ROA) | -15.83% |
| Return on Invested Capital (ROIC) | -23.23% |
| Return on Capital Employed (ROCE) | -40.27% |
| Revenue Per Employee | $175,212 |
| Profits Per Employee | -$326,672 |
| Employee Count | 172 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, AC Immune has paid $3,311 in taxes.
| Income Tax | 3,311 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.72% in the last 52 weeks. The beta is 1.49, so AC Immune's price volatility has been higher than the market average.
| Beta (5Y) | 1.49 |
| 52-Week Price Change | -31.72% |
| 50-Day Moving Average | 2.10 |
| 200-Day Moving Average | 2.91 |
| Relative Strength Index (RSI) | 42.42 |
| Average Volume (20 Days) | 180,435 |
Short Selling Information
| Short Interest | 1.44M |
| Short Previous Month | 1.35M |
| Short % of Shares Out | 3.03% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 7.30 |
Income Statement
In the last 12 months, AC Immune had revenue of $30.14 million and -$56.19 million in losses. Loss per share was -$0.56.
| Revenue | 30.14M |
| Gross Profit | -38.91M |
| Operating Income | -57.80M |
| Pretax Income | -69.76M |
| Net Income | -56.19M |
| EBITDA | -56.16M |
| EBIT | -57.80M |
| Loss Per Share | -$0.56 |
Full Income StatementBalance Sheet
The company has $182.62 million in cash and $5.99 million in debt, giving a net cash position of $176.63 million or $1.79 per share.
| Cash & Cash Equivalents | 182.62M |
| Total Debt | 5.99M |
| Net Cash | 176.63M |
| Net Cash Per Share | $1.79 |
| Equity (Book Value) | 123.89M |
| Book Value Per Share | 1.23 |
| Working Capital | 78.52M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $72.66 million and capital expenditures -$635,635, giving a free cash flow of $78.77 million.
| Operating Cash Flow | 72.66M |
| Capital Expenditures | -635,635 |
| Free Cash Flow | 78.77M |
| FCF Per Share | $0.80 |
Full Cash Flow StatementMargins
Gross margin is -129.12%, with operating and profit margins of -191.80% and -186.44%.
| Gross Margin | -129.12% |
| Operating Margin | -191.80% |
| Pretax Margin | -186.43% |
| Profit Margin | -186.44% |
| EBITDA Margin | -186.36% |
| EBIT Margin | -191.80% |
| FCF Margin | 261.38% |
Dividends & Yields
AC Immune does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.71% |
| Shareholder Yield | -17.71% |
| Earnings Yield | -34.21% |
| FCF Yield | 47.96% |
Analyst Forecast
The average price target for AC Immune is $12.00, which is 622.89% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $12.00 |
| Price Target Difference | 622.89% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 58.18% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AC Immune has an Altman Z-Score of -1.04 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.04 |
| Piotroski F-Score | 4 |